M28 Capital Management LP
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 13, 2025), M28 Capital Management LP reported 9 stock positions worth $58.6 million. Its top holding was Wave Life Sciences (WVE) at 62.8% of the portfolio, followed by Invivyd (IVVD, 11.3%) and TG Therapeutics (TGTX, 9.9%). Compared with Q1 2025, it sold out of 2. The biggest sale was an exit from Bridgebio Pharma (BBIO).
- Most Recent 13F
- Q2 2026
- Location
- STAMFORD, CT
- CIK
- 0001807489
- Portfolio Value
- $58.6M (Q2 2025)
- SEC Filing
- 0000902664-25-003554 ↗ filed Aug 13, 2025
Holdings Value
Holdings 9 stocks · $58.6M
| WVE Wave Life Sciences Ltd. | 62.80% | 5,664,548 | $36.8M | No change |
| IVVD Invivyd Inc. | 11.28% | 9,248,250 | $6.6M | No change |
| TGTX TG Therapeutics Inc. | 9.92% | 161,600 | $5.8M | No change |
| GUTS Fractyl Health Inc. | 5.13% | 1,856,117 | $3.0M | No change |
| PRQR Proqr Therapeutics NV | 3.55% | 1,019,498 | $2.1M | No change |
| CRIS Curis Inc. | 2.06% | 521,059 | $1.2M | No change |
| SLN Silence Therapeutics PLC-ADR | 1.83% | 185,100 | $1.1M | No change |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.82% | 67,400 | $1.1M | No change |
| RCKT Rocket Pharmaceuticals Inc. | 1.61% | 385,680 | $945K | No change |
Portfolio Sells Q1 2025 → Q2 2025
Portfolio Buys Q1 2025 → Q2 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $47.2M | WVE, IVVD, TGTX, ARWR, GUTS |
| Q1 2026 | 9 | $53.8M | WVE, IVVD, TGTX, ARWR, PRQR |
| Q4 2025 | 9 | $137.6M | WVE, IVVD, TGTX, ARWR, GUTS |
| Q3 2025 | 9 | $68.0M | WVE, IVVD, TGTX, GUTS, ARWR |
| Q2 2025 | 9 | $58.6M | WVE, IVVD, TGTX, GUTS, PRQR |
| Q1 2025 | 11 | $73.0M | WVE, TGTX, IVVD, BBIO, RCKT |
| Q4 2024 | 11 | $101.9M | WVE, TGTX, RCKT, IVVD, SWTX |
| Q3 2024 | 11 | $91.0M | WVE, IVVD, RCKT, GUTS, TGTX |
| Q2 2024 | 11 | $77.1M | WVE, IVVD, RCKT, GUTS, SWTX |
| Q1 2024 | 11 | $135.3M | WVE, IVVD, GUTS, RCKT, SLN |